Own report: With the third wave of corona affecting children, trials for immunizations began. But the Serum Institute played a big role in this. The expert committee of the Central Drug Control Agency (DCGI) has banned the second and third trials of the company’s Covavax vaccine for people between the ages of 2 and 18.

Kovavax is being developed in collaboration with the American company NovaVax in collaboration with the Seram Institute of India. Serum had applied to the central drug regulatory body for permission to administer the Kovavax vaccine experimentally to people between the ages of 2 and 18.

Read more, Corona UpdateThe number of daily attacks and deaths increased again, with a total death toll of 4 lakh

Since no country has yet ratified the Kovavax vaccine, India is not allowing the vaccine to be administered to children, adolescents and young people. According to the trial plan, children will be monitored for six months at two-dose intervals of 21 days. But the trial is currently closed due to lack of permission from the Center.

The agency said a total of 920 people between the ages of 2 and 18 would be tested for the Kovavax vaccine. However, the Central Drug Control Agency of India has instructed Seram to first test the vaccine for those over 18 years of age. There, after seeing the results of the third trial, the rate of side effects, the trial of this ticker will be allowed in the body of children.

It is claimed that this vaccine is made for middle and lower class countries including India. The American biotechnology company NovaVax’s NVX-CoV2373 antidote has been named Kovavax after Serum’s company, along with their CovShield.